Researchers at UiT have developed a novel class of antibiotics inspired by small marine antimicrobials and antimicrobial peptides that display high activity against 30 multiresistant clinical isolates of Gram-negative and Gram-positive bacteria. In vitro studies against multi-resistant clinical isolates reveals antimicrobial activity with minimum inhibitory concentration (MIC) values in the range 2 – 16 μg/ml; including activity against ESBL -CARBA producing and colistin resistant bacteria (table). Importantly, the compounds show good selectivity for bacteria vs. human cells (RBCs, HepG2, MRC5). Both compound optimization, toxicity studies and in-vivo efficacy studies are ongoing.
The compounds show activity against Gram-positive and Gram-negative bacteria, including against multi-drug resistant isolates. We foresee several ways the compounds may be developed for clinical use:
The compounds are in lead optimization phase and will require further testing and development before before pre-clinical development. We are now looking for a commercial partner which can contribute towards directing further development towards a license. Patent application is filed.
We are seeking established companies in the field of antibiotics interested in developing a new treatment against multi-resistant Gram-negative and Gram-positive bacteria.
Morten B. Strøm
Stig Olov Magnus Engqvist
Marianne Hegensen Paulsen
Norinnova Technology Transfer AS